Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.70 |
| ▸ | EGFR | P00533 | 8/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | NPM1 | P06748 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846483 | 1.00 | ALK (0.70) | ALKEGFRIGF1RKCNH2NPM1 | |
| SCHEMBL18181786 | 0.83 | ALK (0.66) | ALKEGFRIGF1RKCNH2NPM1 | |
| SCHEMBL18181661 | 0.82 | ALK (1.00) | ALKEGFRMET | |
| SCHEMBL18181711 | 0.79 | ALK (1.00) | ALKEGFRMET | |
| SCHEMBL520365 | 0.77 | ALK (0.80) | ALKKCNH2NPM1INSR | |
| SCHEMBL18181693 | 0.75 | ALK (1.00) | ALKEGFRKCNH2INSR | |
| SCHEMBL18181745 | 0.75 | ALK (0.74) | ALKEGFRMET | |
| SCHEMBL2354282 | 0.73 | IGF1R (0.74) | ALKEGFRIGF1RKCNH2MET | |
| SCHEMBL19920273 | 0.73 | ALK (0.72) | ALKEGFRMET | |
| SCHEMBL30957984 | 0.73 | EGFR (0.63) | ALKEGFRIGF1RKCNH2NPM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440189-B | Fused ring pyrimidine amino derivative, preparation method, intermediate, pharmaceutical composition and application thereof | 广州再极医药科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110078741-B | Fused ring pyrimidine amino derivative, preparation method, intermediate, pharmaceutical composition and application thereof | 广州再极医药科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-106220644-B | Fused ring pyrimidine amino derivative, preparation method, intermediate, pharmaceutical composition and application thereof | 广州再极医药科技有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-111440189-A | Fused ring pyrimidine amino derivative, preparation method, intermediate, pharmaceutical composition and application thereof | 广州再极医药科技有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-10611770-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2020-04-07 | — | — | US | disclosed |
| US-20190177332-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20190177332-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-10259816-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-10259816-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169504-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | 广州再极医药科技有限公司 | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177332-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | WEE1, PDK1, WEE2 | ALK 645/4885EGFR 1865/4885IGF1R 359/4885 |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | PDK1, WEE1, DCK | ALK 770/4885EGFR 2106/4885IGF1R 342/4885 |
| US-10611770-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | WEE1, PDK1, WEE2 | ALK 645/4885EGFR 1865/4885IGF1R 359/4885 |
| US-10259816-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | WEE1, PDK1, WEE2 | ALK 645/4885EGFR 1865/4885IGF1R 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.